Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/Sézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study.

Keila MitsunagaMartine BagotCaroline Ram-WolffEmmanuella GuenovaChristina von GugelbergEmmilia HodakIris Amitay-LaishEvangelia PapadavidConstanze JonakStefanie PorkertJulia ScarisbrickRona ApplewaiteMarie Beylot-BarryJan NicolayPietro QuaglinoJosé Antonio SanchesJade Cury-MartinsDavid Lora-PablosPablo Ortiz

Published in: The British journal of dermatology (2024)

PEG IFN α-2a for MF/SS showed ORR of 53%, TTNT of 9.2 months, superiority of combination regimens in comparison to monotherapy and doses of 180 mcg/weekly related to higher ORR.

Keyphrases

dendritic cells
combination therapy
open label
study protocol
replacement therapy
drug induced